NICE Gives Landmark Nod To Bayer's Vitrakvi
First Histology-Independent Therapy For Patients In England
Executive Summary
Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.
You may also be interested in...
Bayer Q2 Pharma Sales Ravaged By COVID-19
Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.
The Tumor-Agnostic Developer’s Toolkit
In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.
Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.